Company: PHAT
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034183
Chunk: 86

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 16
Chunk 86
---
390

    Net loss

    —

    —

    —

    —

    (201,592
    )

    (201,592
    )

    Balance at December 31, 2023

    57,970,044

    $
    5

    19

    $
    855,921

    $
    (928,685
    )
     
    $
    (72,759
    )

See accompanying notes

F-6

PHATHOM PHARMACEUTICALS, INC. 

Statements of Cash Flows 

(in thousands) 

    Years EndedDecember 31,

    2024

    2023

    Cash flows from operating activities

    Net loss
     
    $
    (334,326
    )
     
    $
    (201,592
    )

    Adjustments to reconcile net loss to net cash used in operating activities:

    Depreciation and amortization

    795

    575

    Stock-based compensation

    24,047

    45,025

    Issuance of PIK interest debt

    3,775

    3,583

    Accrued interest on revenue interest financing liability

    46,111

    24,727

    Amortization of debt discount

    2,192

    1,877

    Inventory reserve

    836

    —

    Other

    5,098

    1,869

    Changes in operating assets and liabilities:

    Prepaid expenses and other current assets

    (7,672
    )

    (8,067
    )

    Accounts receivable, net

    (37,160
    )

    (1,637
    )

    Accounts payable and accrued expenses

    34,936

    6,410

    Accrued interest

    565

    292

    Operating right-of-use assets and lease liabilities

    175

    194

    Inventory

    (6,142
    )

    (9,442
    )

    Other long-term assets

    —

    (1,394
    )

    Net cash used in operating activities

    (266,770
    )

    (137,580
    )

    Cash flows from investing activities

    Cash paid for property and equipment

    (135
    )

    (1,634
    )

    Net cash used in investing activities